SIASUN(SZ:300024) Nan Fang Du Shi Bao·2025-10-14 08:13Core Insights - The company Zhifang has entered the "unicorn" club with a valuation of $1 billion, having completed seven rounds of financing this year, attracting significant investment from firms like Shenzhen Capital Group and PwC Capital [1] - The embodied intelligence sector is experiencing rapid valuation increases and high-frequency financing, with several Chinese companies reaching the $1 billion valuation threshold [1] - Morgan Stanley predicts that by 2050, the global humanoid robot market will deploy 1 billion units, with a market size of $5 trillion, which is approximately double the total revenue of the 20 largest automotive manufacturers in 2024 [2] Company Developments - Zhifang announced a new order for over 1,000 robots worth nearly $500 million, to be deployed at the production base of Huike Co., Ltd., a semiconductor display panel company [5] - The company has previously deployed its Aibao series of wheeled humanoid robots in factories of Dongfeng Liuzhou Motor and Geely Technology [5] Market Dynamics - The rapid increase in valuations has raised concerns about potential bubbles in the industry, with some investors noting that the valuations are influenced by many unquantifiable factors [1] - The valuation logic for embodied intelligence companies often references the automotive industry, suggesting that if the market materializes, it could exceed the automotive sector's overall market size [1] - Chinese embodied intelligence companies are currently valued lower than their U.S. counterparts, partly due to differences in the venture capital ecosystem and the focus on domestic market potential [3][4] Investment Trends - The upcoming IPO of Yushutech is expected to serve as a catalyst for future financing activities in the embodied intelligence sector, potentially raising market valuations due to scarcity effects [2] - Chinese investors tend to prioritize current commercialization performance, contrasting with U.S. companies that can achieve high valuations without significant commercial progress [4]